^
    2d
    A Phase I Evaluation of the Safety and Tolerability of Pirfenidone in Idiopathic Subglottic Stenosis (clinicaltrials.gov)
    P1, N=40, Not yet recruiting, London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
    New P1 trial
    2d
    Bintrafusp alfa for patients with recurrent or metastatic olfactory neuroblastoma. (PubMed, Cancer Immunol Immunother)
    Although the primary endpoint was not met, BA showed a manageable safety profile and a subset of patients derived clinical benefit with prolonged stable disease, including one patient with a complete metabolic response. This first clinical trial of systemic therapy in R/M ONB serves as proof of clinical trials feasibility in this setting and supports further investigation of combinatorial immunotherapy strategies in this patient population. Trial registration ClinicalTrials.gov Identifier: NCT05012098, https://clinicaltrials.gov/ct2/show/NCT05012098. Registered 18 August 2021.
    Journal
    |
    TGFB1 (Transforming Growth Factor Beta 1)
    |
    bintrafusp alfa (M7824)
    3d
    SOFAPI: Impact of Sotatercept on Pulmonary Artery and Right Ventricle Remodeling Imaging Assessed With 68Ga-FAPI PET/CT in Patients With PAH (clinicaltrials.gov)
    P1/2, N=15, Not yet recruiting, University Hospital, Brest | Trial completion date: Dec 2028 --> Jan 2028 | Initiation date: Jan 2026 --> Jul 2026 | Trial primary completion date: Jan 2027 --> Jan 2028
    Trial completion date • Trial initiation date • Trial primary completion date
    |
    Winrevair (sotatercept-csrk)
    4d
    MAXILUS: A Study to Assess Luspatercept in Lower-risk Myelodysplastic Syndrome Participants (clinicaltrials.gov)
    P3, N=106, Active, not recruiting, Bristol-Myers Squibb | Trial completion date: Dec 2027 --> Sep 2027
    Trial completion date
    |
    Reblozyl (luspatercept-aamt)
    4d
    A Study of Sotatercept (MK-7962) in Japanese Children With Pulmonary Arterial Hypertension (PAH) (MK-7962-032) (clinicaltrials.gov)
    P2, N=6, Not yet recruiting, Merck Sharp & Dohme LLC
    New P2 trial
    |
    Winrevair (sotatercept-csrk)
    4d
    HLA-DR+ Schwann Cells Generate the Protumor Cancer-Neuron-Immune Niche in Head and Neck Squamous Cell Carcinoma. (PubMed, Adv Sci (Weinh))
    The tumor suppression effects of CCL2 inhibitor (Pirfenidone) and CXCR3 inhibitor (AMG487) are validated in the orthotopic tumor model. Our findings reveal the mechanism of how HLA-DR+ Schwann cells generate cancer-neuron-immune niche, provide insights into tumor neurology, and lay foundations for therapeutics development for HNSCC patients.
    Journal
    |
    ERBB3 (V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3) • NRG1 (Neuregulin 1) • CXCL10 (Chemokine (C-X-C motif) ligand 10) • CD4 (CD4 Molecule) • CCL2 (Chemokine (C-C motif) ligand 2) • CXCR3 (C-X-C Motif Chemokine Receptor 3) • IL1B (Interleukin 1, beta)
    7d
    Collagen-derived biomarkers reveal distinct fibrotic responses among cancer-associated fibroblasts. (PubMed, Sci Rep)
    Notably, TGF-β1 was the primary driver of PRO-C3, PDGF-AB was the primary driver of PRO-C6, while IL-1α and IL-6 had no effect on PRO-C1, PRO-C3 and PRO-C6 levels. Antifibrotic treatments with ALK5i and Fresolimumab effectively reduced collagen biomarkers elevated by TGF-β1 to baseline levels or below.These results underscore the heterogeneity of CAFs in ECM remodeling, highlighting the need for tailored therapeutic strategies to target tumors exhibiting high fibrotic activity.
    Journal
    |
    IL6 (Interleukin 6) • TGFB1 (Transforming Growth Factor Beta 1)
    |
    fresolimumab (GC 1008)
    10d
    Luspatercept vs Epoetin in Treating Poor Erythroid Engraftment for Hematological Malignancies (clinicaltrials.gov)
    P2/3, N=90, Not yet recruiting, Nanfang Hospital, Southern Medical University
    New P2/3 trial
    |
    Reblozyl (luspatercept-aamt)
    11d
    A Pilot, Open-Label Study of Luspatercept for Patients With Lower Risk Myelodysplastic Syndromes (MDS) (clinicaltrials.gov)
    P2, N=10, Active, not recruiting, M.D. Anderson Cancer Center | Recruiting --> Active, not recruiting | N=40 --> 10
    Enrollment closed • Enrollment change
    |
    Reblozyl (luspatercept-aamt)
    11d
    HARMONIZE: Extension Study of Sotatercept in People With Pulmonary Hypertension (MK-7962-023) (clinicaltrials.gov)
    P2, N=130, Active, not recruiting, Merck Sharp & Dohme LLC | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Winrevair (sotatercept-csrk)
    15d
    ELRISE MF: A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib (clinicaltrials.gov)
    P3, N=324, Not yet recruiting, Takeda
    New P3 trial
    |
    Jakafi (ruxolitinib) • elritercept (KER-050)
    17d
    A Real-World Study to Evaluate Luspatercept in Adults With Transfusion-Dependent Beta-Thalassemia in the Middle East (clinicaltrials.gov)
    P=N/A, N=200, Recruiting, Bristol-Myers Squibb | Initiation date: Feb 2026 --> Jun 2026
    Trial initiation date • Real-world evidence
    |
    Reblozyl (luspatercept-aamt)